Biotech Values

[Mufaso]

I'm listening as well. On the trizepatide SYNERGY-NASH trial I think it is important that the trial's secondary endpoint on fibrosis showed a one stage improvement. Small trial but the first time an incretin has had an effect on fibrosis:

Secondary endpoint of decrease in fibrosis by at least one stage with no worsening of MASH on liver histology was clinically meaningful across doses

It is note worthy that this trial was biopsy confirmed and had some T2D patients in the study population. MDGL and a number of companies targeting NASH are down significantly (12 to 19%) at the time of posting.